European journal of pharmacology · 2026
Inhibitory mechanism of fluoxetine in collagen-induced platelet aggregation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Da Xing-Wen, Fang Peiliang, Li Gaoxiang, Du Meng-Yi, Xu Min, He Ao-Di, Xie Wen, Liu Gang, Liang Ming-Lu, Song Wei, Xu Yun, Zhou Fen, Ming Zhang-Yin
Аннотация
BACKGROUND: Fluoxetine, a selective serotonin reuptake inhibitor, is commonly prescribed as an antidepressant; however, studies have demonstrated that it increases bleeding risk. This study examined the potential mechanisms underlying the effects of fluoxetine on platelet activation.
METHODS: Washed platelets and platelet-rich plasma were used to investigate the effects of fluoxetine on collagen- and collagen-related peptide-induced platelet aggregation and secretion. Flow cytometry was used to measure its effects on P-selectin expression in washed human platelets stimulated with collagen. Western blotting was used to detect protein phosphorylation.
RESULTS: Fluoxetine significantly reduced collagen-induced platelet aggregation in a dose-dependent manner. Fluoxetine decreased the levels of phospholipase C gamma 2 (PLCγ2), spleen tyrosine kinase (Syk), protein kinase B (Akt), and glycogen synthase kinase 3 beta (GSK3β) phosphorylation in the glycoprotein Ⅵ (GPⅥ) signaling pathway, as well as the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the mitogen-activated protein kinase (MAPK) family. However, fluoxetine did not affect p38 MAPK or c-Jun N-terminal kinase (JNK) phosphorylation. 5-HT analogs block the effects of fluoxetine on platelets and downstream signaling pathways of GPⅥ. Administration of an additional 5-HT2 receptor antagonist, ketanserin, resulted in a reduction of platelet aggregation levels; however, the values remained statistically distinct from those observed in the fluoxetine-alone group.
CONCLUSIONS: Fluoxetine attenuates collagen-induced platelet activation and interferes with the Syk-PLCγ2-Akt-GSK3β and ERK1/2 signaling pathways; this effect may be attributed to its dual inhibition of 5-HT receptors and Serotonin transporters (SERTs).
METHODS: Washed platelets and platelet-rich plasma were used to investigate the effects of fluoxetine on collagen- and collagen-related peptide-induced platelet aggregation and secretion. Flow cytometry was used to measure its effects on P-selectin expression in washed human platelets stimulated with collagen. Western blotting was used to detect protein phosphorylation.
RESULTS: Fluoxetine significantly reduced collagen-induced platelet aggregation in a dose-dependent manner. Fluoxetine decreased the levels of phospholipase C gamma 2 (PLCγ2), spleen tyrosine kinase (Syk), protein kinase B (Akt), and glycogen synthase kinase 3 beta (GSK3β) phosphorylation in the glycoprotein Ⅵ (GPⅥ) signaling pathway, as well as the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the mitogen-activated protein kinase (MAPK) family. However, fluoxetine did not affect p38 MAPK or c-Jun N-terminal kinase (JNK) phosphorylation. 5-HT analogs block the effects of fluoxetine on platelets and downstream signaling pathways of GPⅥ. Administration of an additional 5-HT2 receptor antagonist, ketanserin, resulted in a reduction of platelet aggregation levels; however, the values remained statistically distinct from those observed in the fluoxetine-alone group.
CONCLUSIONS: Fluoxetine attenuates collagen-induced platelet activation and interferes with the Syk-PLCγ2-Akt-GSK3β and ERK1/2 signaling pathways; this effect may be attributed to its dual inhibition of 5-HT receptors and Serotonin transporters (SERTs).